Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 0.79 |
| ▸ | JAK1 | P23458 | 7/20 | 0.61 |
| ▸ | JAK3 | P52333 | 3/20 | 0.61 |
| ▸ | TYK2 | P29597 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14331926 | 1.00 | JAK2 (1.00) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL21799094 | 0.93 | JAK2 (1.00) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL14377472 | 0.93 | JAK2 (1.00) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL14377573 | 0.92 | JAK2 (1.00) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL21799083 | 0.92 | JAK2 (1.00) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL14331876 | 0.90 | JAK2 (0.82) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL19321837 | 0.90 | JAK2 (0.83) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL14331984 | 0.89 | JAK2 (0.80) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL17059966 | 0.88 | JAK2 (0.79) | JAK2AXLJAK1JAK3TYK2 | |
| SCHEMBL14331950 | 0.88 | JAK2 (1.00) | JAK2AXLJAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565229-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119768166-A | Treatment of urticaria using JAK inhibitors | 因赛特公司 | 2025-04-04 | — | — | CN | claimed |
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION | 2024-02-22 | — | — | US | claimed |
| WO-2024030600-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION (US) | 2024-02-08 | — | — | WO | claimed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | claimed |
| US-20260021096-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORPORATION (US) | 2026-01-22 | — | — | US | disclosed |
| US-12498382-B2 | Biomarkers for vitiligo | INCYTE CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250367202-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250325664-A1 | COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-12360120-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2025-07-15 | — | — | US | disclosed |
| US-12336998-B2 | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | INCYTE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-20220175731-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | INCYTE CORPORATION | 2022-06-09 | — | — | US | disclosed |
| US-20220177491-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2022-06-09 | — | — | US | disclosed |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | INCYTE CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-11304949-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | INCYTE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220040187-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | INCYTE CORPORATION | 2022-02-10 | — | — | US | disclosed |
| US-20220024934-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | INCYTE CORPORATION | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336998-B2 | JAK1 pathway inhibitors for the treatment of cytokine-related disorders | JAK1, IRAK1, STAT3 | JAK2 8/4885AXL 508/4885JAK1 1/4885 |
| US-11304949-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885AXL 2137/4885JAK1 1/4885 |
| US-12360120-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | JAK2 38/4885AXL 3882/4885JAK1 7/4885 |
| US-12498382-B2 | Biomarkers for vitiligo | TSG101, JAK3, IFNG | JAK2 13/4885AXL 2777/4885JAK1 5/4885 |
| US-20260021096-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885AXL 274/4885JAK1 1/4885 |
| US-20250325664-A1 | COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR | JAK1, CSF3R, JAK3 | JAK2 5/4885AXL 1049/4885JAK1 1/4885 |
| US-20220040187-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | JAK1, IRAK1, STAT3 | JAK2 8/4885AXL 508/4885JAK1 1/4885 |
| US-20220024934-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | PIK3CD, PIK3CA, PIK3CG | JAK2 75/4885AXL 486/4885JAK1 43/4885 |
| US-20220175731-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGO | JAK1, JAK3, JAK2 | JAK2 3/4885AXL 924/4885JAK1 1/4885 |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | JAK1, JAK3, JAK2 | JAK2 3/4885AXL 1288/4885JAK1 1/4885 |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885AXL 559/4885JAK1 1/4885 |
| US-20250367202-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | JAK1, IRAK1, STAT3 | JAK2 8/4885AXL 508/4885JAK1 1/4885 |
| US-20220177491-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R1 | JAK2 39/4885AXL 411/4885JAK1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.